menu

Our news

HomeOur news
HomeOur news

Our company news

  • Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection

    Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection

    posted in Our news by myrcludex.admin

    Hepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with tenofovir in chronically HBV/HDV сo-infected patients. 120 subjects will be enrolled in 20 centers in Russia and Germany.

    ...

    read the rest

    23 03, 16
  • Press Release, Moscow, October, 2014

    Press Release, Moscow, October, 2014

    posted in Our news by myrcludex.admin

    Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta

    ...

    read the rest

    01 10, 14